Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.

Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, Wilhelm B, Pfützner A

Diabetic medicine : a journal of the British Diabetic Association1 Sept 2012Cited by 61 (Europe PMC)

PMID22288732DOI10.1111/j.1464-5491.2012.03589.xPepBankPUB-22288732

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide lowered HbA1c from 6.3% to 5.8%.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide lowered HbA1c from 6.3% to 5.8%.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Measurements
HbA1c
6.3%
baseline
HbA1c
5.8%
on liraglutide
Source sentences
Summary
HbA(1c) levels declined from 45 ± 4 mmol/mol (6.3 ± 0.4%; mean ± SD) to 40 ± 3 mmol/mol (5.8 ± 0.3%) during liraglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide reduced asymmetric dimethylarginine from 0.39 to 0.35 μmol/l.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide lowered a blood vessel risk marker (asymmetric dimethylarginine).
Peptide
Liraglutide
Outcome
DecreaseAsymmetric dimethylarginine
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Measurements
ADMA
0.39 µmol/l
baseline
ADMA
0.35 µmol/l
12 weeks
Source sentences
Summary
Asymmetric dimethylarginin was reduced by liraglutide treatment from 0.39 ± 0.08 to 0.35 ± 0.06 μmol/l, E-selectin from 43.6 ± 15.4 to 40.8 ± 15.1 ng/ml, plasminogen activator inhibitor 1 from 861.6 ± 584.3 to 666.1 ± 499.4 ng/ml and intact proinsulin from 9.0 ± 7.2 to 7.0 ± 4.8 pmol/l at 12 weeks of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide reduced E-selectin from 43.6 to 40.8 ng/ml.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide lowered a blood vessel lining marker (E-selectin).
Peptide
Liraglutide
Outcome
DecreaseE-selectin
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Measurements
E-selectin
43.6 ng/ml
baseline
E-selectin
40.8 ng/ml
12 weeks
Source sentences
Summary
Asymmetric dimethylarginin was reduced by liraglutide treatment from 0.39 ± 0.08 to 0.35 ± 0.06 μmol/l, E-selectin from 43.6 ± 15.4 to 40.8 ± 15.1 ng/ml, plasminogen activator inhibitor 1 from 861.6 ± 584.3 to 666.1 ± 499.4 ng/ml and intact proinsulin from 9.0 ± 7.2 to 7.0 ± 4.8 pmol/l at 12 weeks of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide reduced plasminogen activator inhibitor 1 from 861.6 to 666.1 ng/ml.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide lowered a blood clotting marker (PAI-1).
Peptide
Liraglutide
Outcome
DecreasePlasminogen activator inhibitor 1
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Measurements
PAI-1
861.6 ng/ml
baseline
PAI-1
666.1 ng/ml
12 weeks
Source sentences
Summary
Asymmetric dimethylarginin was reduced by liraglutide treatment from 0.39 ± 0.08 to 0.35 ± 0.06 μmol/l, E-selectin from 43.6 ± 15.4 to 40.8 ± 15.1 ng/ml, plasminogen activator inhibitor 1 from 861.6 ± 584.3 to 666.1 ± 499.4 ng/ml and intact proinsulin from 9.0 ± 7.2 to 7.0 ± 4.8 pmol/l at 12 weeks of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873204
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide reduced intact proinsulin from 9.0 to 7.0 pmol/l.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide lowered intact proinsulin from 9.0 to 7.0 pmol/l.
Peptide
Liraglutide
Outcome
DecreaseIntact proinsulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Measurements
Intact proinsulin
9 pmol/l
baseline
Intact proinsulin
7 pmol/l
12 weeks
Source sentences
Summary
Asymmetric dimethylarginin was reduced by liraglutide treatment from 0.39 ± 0.08 to 0.35 ± 0.06 μmol/l, E-selectin from 43.6 ± 15.4 to 40.8 ± 15.1 ng/ml, plasminogen activator inhibitor 1 from 861.6 ± 584.3 to 666.1 ± 499.4 ng/ml and intact proinsulin from 9.0 ± 7.2 to 7.0 ± 4.8 pmol/l at 12 weeks of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873205
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide increased the retinal microvascular response to flicker light from 7.0% to 15.4% at 6 weeks and 11.1% at 12 weeks.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide improved the response of small eye blood vessels to flicker light.
Peptide
Liraglutide
Outcome
IncreaseMicrovascular response to flicker light
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Measurements
Flicker light response
7%
baseline
Flicker light response
15.4%
6 weeks
Flicker light response
11.1%
12 weeks
Source sentences
Summary
The microvascular response to flicker light increased from 7.0 ± 15.1 to 15.4 ± 11.5% after 6 weeks and to 11.1 ± 9.9% after 12 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873206
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide did not change high-sensitivity C-reactive protein.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide did not change the inflammation marker hs-CRP.
Peptide
Liraglutide
Outcome
No significant changeHigh-sensitivity C-reactive protein
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Source sentences
Summary
No change could be observed for high-sensitivity C-reactive protein, monocyte chemotactic protein 1, vascular cell adhesion molecule or arterial stiffness parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873207
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide did not change monocyte chemotactic protein 1.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide did not change the inflammation marker MCP-1.
Peptide
Liraglutide
Outcome
No significant changeMonocyte chemotactic protein 1
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Source sentences
Summary
No change could be observed for high-sensitivity C-reactive protein, monocyte chemotactic protein 1, vascular cell adhesion molecule or arterial stiffness parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873208
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide did not change vascular cell adhesion molecule.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide did not change the blood vessel marker VCAM.
Peptide
Liraglutide
Outcome
No significant changeVascular cell adhesion molecule
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Source sentences
Summary
No change could be observed for high-sensitivity C-reactive protein, monocyte chemotactic protein 1, vascular cell adhesion molecule or arterial stiffness parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873209
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes well controlled on metformin, adding liraglutide did not change arterial stiffness parameters.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide did not change how stiff the arteries were.
Peptide
Liraglutide
Outcome
No significant changeArterial stiffness parameters
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Studied dose
1.2 mg for 6 weeks, then 1.8 mg · 12 weeksAs given in this study (human).
Source sentences
Summary
No change could be observed for high-sensitivity C-reactive protein, monocyte chemotactic protein 1, vascular cell adhesion molecule or arterial stiffness parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy.
Report a problemFND-2228873210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01208012

Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

ikfe-CRO GmbHn = 44Apr 2010 to Nov 2010

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 15 Mar 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.